Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Consortium (DKTK) Core-Center Heidelberg, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Division of Molecular and Translational Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), 69120 Heidelberg, Germany.
Int J Mol Sci. 2023 Mar 7;24(6):5118. doi: 10.3390/ijms24065118.
Reports of concurrent sparing of normal tissue and iso-effective treatment of tumors at ultra-high dose-rates (uHDR) have fueled the growing field of FLASH radiotherapy. However, iso-effectiveness in tumors is often deduced from the absence of a significant difference in their growth kinetics. In a model-based analysis, we investigate the meaningfulness of these indications for the clinical treatment outcome. The predictions of a previously benchmarked model of uHDR sparing in the "UNIfied and VERSatile bio response Engine" (UNIVERSE) are combined with existing models of tumor volume kinetics as well as tumor control probability (TCP) and compared to experimental data. The potential TCP of FLASH radiotherapy is investigated by varying the assumed dose-rate, fractionation schemes and oxygen concentration in the target. The developed framework describes the reported tumor growth kinetics appropriately, indicating that sparing effects could be present in the tumor but might be too small to be detected with the number of animals used. The TCP predictions show the possibility of substantial loss of treatment efficacy for FLASH radiotherapy depending on several variables, including the fractionation scheme, oxygen level, and DNA repair kinetics. The possible loss of TCP should be seriously considered when assessing the clinical viability of FLASH treatments.
关于超高剂量率(uHDR)下正常组织的同步保护和肿瘤等效治疗的报告,推动了 FLASH 放射治疗领域的发展。然而,肿瘤的等效应通常是根据其生长动力学没有显著差异来推断的。在基于模型的分析中,我们研究了这些指标对临床治疗结果的意义。将之前在“UNIfied 和 VERSatile bio response Engine”(UNIVERSE)中对 uHDR 保护进行基准测试的模型的预测与肿瘤体积动力学的现有模型以及肿瘤控制概率(TCP)相结合,并与实验数据进行了比较。通过改变假设的剂量率、分割方案和靶区中的氧浓度,研究了 FLASH 放射治疗的潜在 TCP。所开发的框架适当地描述了报告的肿瘤生长动力学,表明在肿瘤中可能存在保护效应,但可能太小而无法用所使用的动物数量检测到。TCP 预测表明,FLASH 放射治疗的治疗效果可能会有实质性损失,这取决于几个变量,包括分割方案、氧水平和 DNA 修复动力学。在评估 FLASH 治疗的临床可行性时,应该认真考虑 TCP 损失的可能性。